Clinical Trials Browser

Active not recruiting × olaparib × Gastrointestinal × Clear all

NCT04548752 2026-03-18

Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations

Phase 2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT03212274 2026-02-19

Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations

Phase 2 Active not recruiting

CNSGastrointestinal

Glioblastoma, Glioma, Cholangiocarcinoma

NCT03155620 2026-02-10

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

Phase 2 Active not recruiting

CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Xanthogranuloma, Juvenile, Central Nervous System Neoplasms, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor, Histiocytic Sarcoma

NCT02734004 2026-01-29

MEDIOLA

Phase 1/2 Active not recruiting

264 enrolled 32 charts

BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Small Cell Lung Carcinoma

NCT06630325 2026-01-07

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

Phase 2 Active not recruiting

GastrointestinalGenitourinaryGynecologic

Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT04209686 2025-12-03

Paclitaxel, Pembrolizumab and Olaparib in Previously Treated Advanced Gastric Adenocarcinoma

Phase 2 Active not recruiting

Gastrointestinal

Stomach Neoplasms

NCT02484404 2025-11-25

Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...

Phase 1/2 Active not recruiting

BreastGastrointestinal

Breast Neoplasms, Colorectal Neoplasms

NCT03878095 2025-11-17

Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors

Phase 2 Active not recruiting

Gastrointestinal

Cholangiocarcinoma

NCT05379972 2025-07-16

Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers

Phase 2 Active not recruiting

Gastrointestinal

Stomach Neoplasms

NCT03579784 2024-04-19

Biomarker-oriented Study of Durvalumab (MEDI4736) in Combination With Olaparib and Paclitaxel in Gastric Cancer

Phase 2 Active not recruiting

Gastrointestinal

Advanced Gastric Cancer

NCT04298021 2024-04-19

DDR-Umbrella Study of DDR Targeting Agents in Advanced Biliary Tract Cancer

Phase 2 Active not recruiting

Gastrointestinal

Bile Duct Neoplasms